Business Wire

AMAZFIT

2.2.2024 15:58:27 CET | Business Wire | Press release

Share
Kelvin Kiptum Breaks Limits With Amazfit

Amazfit, a leading global smart wearables brand owned by Zepp Health (NYSE: ZEPP), a health technology company, has today announced its groundbreaking partnership with Kelvin Kiptum, the men's marathon world record holder and only athlete to complete a marathon in under two hours and one minute. As Amazfit’s ambassador, Kiptum will utilize the Amazfit Cheetah Pro to manage training and races, and the Amazfit Helio Ring to optimize recovery, ahead of marathon races in Rotterdam and Paris.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240201514405/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Amazfit ambassador Kelvin Kiptum set to break marathon world record (Graphic: Business Wire)

Zepp Health expressed enthusiasm for this dynamic partnership. Pengtao Yu, VP of Industrial Design, Brand & Consumer Marketing, stated: "We are thrilled about the collaboration between Amazfit and Kelvin Kiptum. As a health technology company, we are proud to support Kelvin's quest to break records and inspire individuals worldwide to pursue their own health and fitness goals. This partnership is a testament to our commitment to empowering people to lead healthier lives through intelligent healthcare fitness solutions."

Kelvin's recent marathon achievement in Chicago, clocking a remarkable 2:00:35, sets the stage for an extraordinary collaboration. Conquering recent marathons in Valencia and London, the 24-year-old runner aims to shatter the 2-hour mark in Rotterdam this April, and clinch gold at the 2024 Olympics in Paris.

To aid his preparation, Kelvin will wear Amazfit’s Cheetah Pro. This specialist running watch features MaxTrack™ dual-band circularly-polarized GPS antenna, with 99.5% the accuracy of a professional GPS locator, along with the innovative Zepp Coach™ - an AI solution generating tailored plans for athletes looking for optimal marathon preparation. This cutting-edge technology will support Kelvin as he hones the finer details of his training.

Kelvin Kiptum shares his excitement about the collaboration, stating, "Teaming up with Amazfit for this groundbreaking journey is truly exciting. The Amazfit Cheetah Pro has become an integral part of my training regimen. As I aim to break the 2-hour mark in Rotterdam and pursue gold at the Paris Olympics, I am confident that Amazfit will be my ultimate ally in pushing the limits of human potential. Together, we are set to redefine what's possible."

This partnership extends beyond the track, with Kiptum also utilizing recently-announced Amazfit Helio Ring to take control of his recovery, with in-depth analysis of sleep quality, mental and physical Readiness, and emotional state enabled by the smart ring's BioTracker™ and EDA sensors.

The symbiosis between Amazfit and Kelvin Kiptum is emblematic of a shared commitment to breaking limits. Just as the brand's smartwatch and smart-ring are crafted for athletes seeking to push boundaries with the support of cutting-edge technology, Kelvin Kiptum continuously exemplifies the limitless potential of human ability.

By forging strategic partnerships with elite athletes like Kelvin Kiptum, Amazfit aims to create a platform that transcends geographical boundaries, providing valuable insights into performance, training, and endurance for aspiring and professional athletes.

The Amazfit Cheetah Pro is available at Amazfit.com and select retailers worldwide. The Amazfit Helio ring will be released later this spring.

For more information, visit https://www.amazfit.com/en

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240201514405/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release

Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh

Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release

- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur

Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release

Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i

Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release

Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up

Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye